CLAIMS

1. Use of a compound having the formula:



or a pharmaceutically acceptable salt thereof, wherein

R^1 is a member selected from the group consisting of C_3-C_4 alkyl, C_3-C_5 cycloalkyl, phenyl, and 5- to 6-membered heteroaryl, wherein each R^1 is optionally substituted with from 1-3 R^a;

R^2 is a member selected from the group consisting of phenyl, phenyl-C_1-C_4 alkyl, 5- to 6- membered heteroaryl and 5- to 6-membered heteroaryl-C_1-C_4 alkyl, wherein each R^2 is optionally substituted with from 1-5 R^b;

R^3 is a member selected from the group consisting of C_1-C_4 alkyl, C_3-C_4 cycloalkyl, and 4- to 7-membered heterocycloalkyl, wherein each R^3 is optionally substituted with from 1-3 R^c;

R^4 is H;

X is a member selected from the group consisting of H and F;

each R^a is independently selected from the group consisting of halo, CN, hydroxyl, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_1-C_4 alkoxy, phenyl, phenyl-C_1-C_4 alkyl, phenyl-C_1-C_4 alkoxy, phenoxy, -COR^{a1}, -CO_2R^{a1}, -SO_2R^{a1}, -$SO_2NR^{a1}R^{a2}$, and -$CONR^{a1}R^{a2}$, wherein each R^{a1} and R^{a2} is independently selected from the group consisting of H, C_1-C_4 alkyl and phenyl, or optionally R^{a1} and R^{a2} when attached to a nitrogen atom are combined to form a 4- to 6-membered ring;

each R^b is independently selected from the group consisting of halo, CN, hydroxyl, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_1-C_4 alkoxy, phenoxy, phenyl-C_1-C_4 alkoxy, methylenedioxy, difluoromethylenedioxy, -COR^{b1}, -CO_2R^{b1}, -SO_2R^{b1}, -$SO_2NR^{b1}R^{b2}$, $CONR^{b1}R^{b2}$, $NR^{b1}R^{b2}$, 5- to 6-membered heteroaryl, and 5- to 6-membered heterocyclyl optionally substituted with oxo, wherein each R^{b1} and R^{b2} is independently selected from the group consisting of H and C_1-C_4 alkyl or optionally R^{b1} and R^{b2} when attached to a nitrogen atom are combined to form a 4- to 6- membered ring; and each R^c is independently selected from the group consisting of halo, hydroxyl and C_1-C_2 alkoxy,

in the manufacture of a medicament, for treating hypertrophic cardiomyopathy (HCM), in a subject in need thereof.

2. The use of claim 1, wherein said treatment reduces left ventricular outflow obstruction in the subject.

3. Use of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for treating a disease or disorder selected from the group consisting of diastolic heart failure with preserved ejection fraction, ischemic heart disease, angina pectoris, and restrictive cardiomyopathy, in a subject in need thereof.

4. Use of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof, in the manufacture of medicament for treating left ventricular hypertrophy, in a subject in need thereof.

5. The use of claim 4, wherein the subject is suffering from chronic mitral regurgitation, chronic aortic stenosis, and chronic systemic hypertension.

6. The use of claim 5, wherein said medicament is to be administered in conjunction with one or more therapies selected from the group consisting of valve repair, valve replacement, and effective antihypertensive therapy.

7. Use of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof , in the manufacture of a medicament for treating hypertrophic cardiomyopathy (HCM), in a subject in need thereof , wherein said medicament is to be administered in combination with one or more therapies that retard the progression of heart failure by down-regulating neurohormonal stimulation of the heart and attempt to prevent cardiac remodeling.

8. The use of claim 7, wherein the one or more therapies that retard the progression of heart failure by down-regulating neurohormonal stimulation of the heart and attempt to prevent cardiac remodeling are selected from the group consisting of ACE inhibitors, angiotensin receptor blockers (ARBs), β-blockers, aldosterone receptor antagonists, and neural endopeptidase inhibitors.

9. Use of a compound of claim 1 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating hypertrophic cardiomyopathy (HCM), in a subject in need thereof, wherein said medicament is to be administered in combination with one or more therapies that improve cardiac function by stimulating cardiac contractility.

10. The use of claim 9, wherein the one or more therapies that improve cardiac function by stimulating cardiac contractility are selected from positive inotropic agents.

11. The use of claim 10, wherein the positive inotropic agents are selected from the group consisting of milrinone and dobutamine.

12. Use of a compound of claim 1 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating hypertrophic cardiomyopathy (HCM), in a subject in need thereof, wherein said medicament is to be administered in combination with one or more therapies that reduce cardiac preload or afterload.

13. The use of claim 12, wherein the one or more therapies that reduce cardiac preload or afterload are selected from the group consisting of diuretics and vasodilators.

14. The use of claim 13, wherein the diuretic is furosemide.

15. The use of claim 13, wherein the vasodilator is selected from the group consisting of calcium channel blockers, phosphodiesterase inhibitors, endothelin receptor antagonists, renin inhibitors, and smooth muscle myosin modulators.

16. The use of any one of claims 1-15, wherein the compound is selected from:


,

,

,

,

,

,

,

,

,

,

,

or a pharmaceutically acceptable salt thereof.

17. The use of any one of claims 1-15, wherein the compound is


,

or a pharmaceutically acceptable salt thereof.